367 related articles for article (PubMed ID: 27907203)
1. TP53 Polymorphisms and Colorectal Cancer Risk in Patients with Lynch Syndrome in Taiwan: A Retrospective Cohort Study.
Kamiza AB; Hsieh LL; Tang R; Chien HT; Lai CH; Chiu LL; Lo TP; Hung KY; You JF; Wang WC; Hsiung CA; Yeh CC
PLoS One; 2016; 11(12):e0167354. PubMed ID: 27907203
[TBL] [Abstract][Full Text] [Related]
2. Risk Factors Associated with Colorectal Cancer in a Subset of Patients with Mutations in MLH1 and MSH2 in Taiwan Fulfilling the Amsterdam II Criteria for Lynch Syndrome.
Kamiza AB; Hsieh LL; Tang R; Chien HT; Lai CH; Chiu LL; Lo TP; Hung KY; Wang CY; You JF; Hsiung CA; Yeh CC
PLoS One; 2015; 10(6):e0130018. PubMed ID: 26053027
[TBL] [Abstract][Full Text] [Related]
3. Polymorphisms of xenobiotic-metabolizing genes and colorectal cancer risk in patients with lynch syndrome: A retrospective cohort study in Taiwan.
Kamiza AB; You JF; Wang WC; Tang R; Chang CY; Chien HT; Lai CH; Chiu LL; Lo TP; Hung KY; Hsiung CA; Yeh CC
Environ Mol Mutagen; 2018 Jan; 59(1):69-78. PubMed ID: 28714190
[TBL] [Abstract][Full Text] [Related]
4.
Kamiza AB; Wang WC; You JF; Tang R; Wang YT; Chien HT; Lai CH; Chiu LL; Lo TP; Hung KY; Hsiung CA; Yeh CC
Anticancer Res; 2018 Oct; 38(10):5983-5990. PubMed ID: 30275229
[TBL] [Abstract][Full Text] [Related]
5. DNA repair gene polymorphisms and risk of early onset colorectal cancer in Lynch syndrome.
Reeves SG; Meldrum C; Groombridge C; Spigelman A; Suchy J; Kurzawski G; Lubinski J; Scott RJ
Cancer Epidemiol; 2012 Apr; 36(2):183-9. PubMed ID: 21974800
[TBL] [Abstract][Full Text] [Related]
6. Genotype and haplotype analysis of cell cycle genes in sporadic colorectal cancer in the Czech Republic.
Polakova V; Pardini B; Naccarati A; Landi S; Slyskova J; Novotny J; Vodickova L; Bermejo JL; Hanova M; Smerhovsky Z; Tulupova E; Kumar R; Hemminki K; Vodicka P
Hum Mutat; 2009 Apr; 30(4):661-8. PubMed ID: 19224585
[TBL] [Abstract][Full Text] [Related]
7. Aspirin, Ibuprofen, and the Risk of Colorectal Cancer in Lynch Syndrome.
Ait Ouakrim D; Dashti SG; Chau R; Buchanan DD; Clendenning M; Rosty C; Winship IM; Young JP; Giles GG; Leggett B; Macrae FA; Ahnen DJ; Casey G; Gallinger S; Haile RW; Le Marchand L; Thibodeau SN; Lindor NM; Newcomb PA; Potter JD; Baron JA; Hopper JL; Jenkins MA; Win AK
J Natl Cancer Inst; 2015 Sep; 107(9):. PubMed ID: 26109217
[TBL] [Abstract][Full Text] [Related]
8. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome.
Bonadona V; Bonaïti B; Olschwang S; Grandjouan S; Huiart L; Longy M; Guimbaud R; Buecher B; Bignon YJ; Caron O; Colas C; Noguès C; Lejeune-Dumoulin S; Olivier-Faivre L; Polycarpe-Osaer F; Nguyen TD; Desseigne F; Saurin JC; Berthet P; Leroux D; Duffour J; Manouvrier S; Frébourg T; Sobol H; Lasset C; Bonaïti-Pellié C;
JAMA; 2011 Jun; 305(22):2304-10. PubMed ID: 21642682
[TBL] [Abstract][Full Text] [Related]
9. Colorectal cancer susceptibility loci on chromosome 8q23.3 and 11q23.1 as modifiers for disease expression in Lynch syndrome.
Talseth-Palmer BA; Brenne IS; Ashton KA; Evans TJ; McPhillips M; Groombridge C; Suchy J; Kurzawski G; Spigelman A; Lubinski J; Scott RJ
J Med Genet; 2011 Apr; 48(4):279-84. PubMed ID: 21097774
[TBL] [Abstract][Full Text] [Related]
10. Survival Outcome and Risk of Metachronous Colorectal Cancer After Surgery in Lynch Syndrome.
Kim TJ; Kim ER; Hong SN; Kim YH; Huh JW; Park YA; Cho YB; Yun SH; Kim HC; Lee WY; Kim K; Kim K; Chang DK
Ann Surg Oncol; 2017 Apr; 24(4):1085-1092. PubMed ID: 27766559
[TBL] [Abstract][Full Text] [Related]
11. Combined analysis of three Lynch syndrome cohorts confirms the modifying effects of 8q23.3 and 11q23.1 in MLH1 mutation carriers.
Talseth-Palmer BA; Wijnen JT; Brenne IS; Jagmohan-Changur S; Barker D; Ashton KA; Tops CM; Evans TJ; McPhillips M; Groombridge C; Suchy J; Kurzawski G; ; Spigelman A; Møller P; Morreau HM; Van Wezel T; Lubinski J; Vasen HF; Scott RJ
Int J Cancer; 2013 Apr; 132(7):1556-64. PubMed ID: 22987364
[TBL] [Abstract][Full Text] [Related]
12. Contribution of the MLH1 -93G>a promoter polymorphism in modulating susceptibility risk in Malaysian colorectal cancer patients.
Nizam ZM; Abdul Aziz AA; Kaur G; Abu Hassan MR; Mohd Sidek AS; Yeh LY; Mazuwin M; Ankathil R
Asian Pac J Cancer Prev; 2013; 14(2):619-24. PubMed ID: 23621208
[TBL] [Abstract][Full Text] [Related]
13. Type 2 diabetes mellitus, blood cholesterol, triglyceride and colorectal cancer risk in Lynch syndrome.
Dashti SG; Li WY; Buchanan DD; Clendenning M; Rosty C; Winship IM; Macrae FA; Giles GG; Hardikar S; Hua X; Thibodeau SN; Figueiredo JC; Casey G; Haile RW; Gallinger S; Le Marchand L; Newcomb PA; Potter JD; Lindor NM; Hopper JL; Jenkins MA; Win AK
Br J Cancer; 2019 Nov; 121(10):869-876. PubMed ID: 31551580
[TBL] [Abstract][Full Text] [Related]
14. MDM2 SNP309 T>G alone or in combination with the TP53 R72P polymorphism does not appear to influence disease expression and age of diagnosis of colorectal cancer in HNPCC patients.
Talseth BA; Meldrum C; Suchy J; Kurzawski G; Lubinski J; Scott RJ
Int J Cancer; 2007 Feb; 120(3):563-5. PubMed ID: 17096342
[TBL] [Abstract][Full Text] [Related]
15. Risk factors for metachronous colorectal cancer in Lynch syndrome patients: a registry-based observational mono-institutional study cohort.
Signoroni S; Piozzi GN; Ricci MT; Mancini A; Morabito A; Bertario L; Vitellaro M
Int J Clin Oncol; 2020 Sep; 25(9):1644-1652. PubMed ID: 32430733
[TBL] [Abstract][Full Text] [Related]
16. One to 2-year surveillance intervals reduce risk of colorectal cancer in families with Lynch syndrome.
Vasen HF; Abdirahman M; Brohet R; Langers AM; Kleibeuker JH; van Kouwen M; Koornstra JJ; Boot H; Cats A; Dekker E; Sanduleanu S; Poley JW; Hardwick JC; de Vos Tot Nederveen Cappel WH; van der Meulen-de Jong AE; Tan TG; Jacobs MA; Mohamed FL; de Boer SY; van de Meeberg PC; Verhulst ML; Salemans JM; van Bentem N; Westerveld BD; Vecht J; Nagengast FM
Gastroenterology; 2010 Jun; 138(7):2300-6. PubMed ID: 20206180
[TBL] [Abstract][Full Text] [Related]
17. Genetic polymorphisms of TP53 (rs1042522) and MDM2 (rs2279744) and colorectal cancer risk: An updated meta-analysis based on 59 case-control studies.
Elshazli RM; Toraih EA; Elgaml A; Kandil E; Fawzy MS
Gene; 2020 Apr; 734():144391. PubMed ID: 32001373
[TBL] [Abstract][Full Text] [Related]
18. Cumulative risks of colorectal cancer in Han Chinese patients with Lynch syndrome in Taiwan.
Kamiza AB; Wang WC; You JF; Tang R; Chien HT; Lai CH; Chiu LL; Lo TP; Hung KY; Hsiung CA; Yeh CC
Sci Rep; 2021 Apr; 11(1):8899. PubMed ID: 33903664
[TBL] [Abstract][Full Text] [Related]
19. The additive effect of p53 Arg72Pro and RNASEL Arg462Gln genotypes on age of disease onset in Lynch syndrome patients with pathogenic germline mutations in MSH2 or MLH1.
Krüger S; Engel C; Bier A; Silber AS; Görgens H; Mangold E; Pagenstecher C; Holinski-Feder E; von Knebel Doeberitz M; Royer-Pokora B; Dechant S; Pox C; Rahner N; Müller A; Schackert HK;
Cancer Lett; 2007 Jul; 252(1):55-64. PubMed ID: 17224235
[TBL] [Abstract][Full Text] [Related]
20. Redundant DNA methylation in colorectal cancers of Lynch-syndrome patients.
Alemayehu A; Sebova K; Fridrichova I
Genes Chromosomes Cancer; 2008 Oct; 47(10):906-14. PubMed ID: 18618713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
